 CUPERTINO, Calif., Feb. 4, 2021 PRNewswire -- DURECT Corporation Nasdaq: DRRX DURECT, a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its... 